Drug Trial Radar · NCT03396068
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
72
Planned (sponsor's estimate)
Start
Dec 1, 2019
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- NeuroRx, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Target Health Inc.
- First posted
- Jan 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketamine HCL) for rapid stabilization of symptoms of depression and suicidal ideation followed by oral NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for maintenance of stabilization from symptoms of depression and suicidal ideation. NRX-101 has been awarded Fast Track and Breakthrough Therapy Designation by the US Food and Drug Administration. The SevereBD study will test the hypothesis that NRX-101 is superior to lurasidone alone in maintaining remission from symptoms of depression (primary endpoint), clinical relapse (declared secondary endpoint), and suicidal ideation or behavior (declared secondary endpoint) over a six week period of twice-daily oral dosing.
Conditions
- Bipolar Depression
- Suicidal Ideation
Interventions
NRX-101Drug
NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
Lurasidone HClDrug
Lurasidone HCl will be given twice a day by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- MADRS-10Time frame: Six weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Research Site, Birmingham
Birmingham, Alabama
Research Centers of America
Hollywood, Florida
JP Smith Hospital
Fort Worth, Texas
Research Site, Houston
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.